Status:
COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.Despite treatment, the 5-year overall survival rates for MIBC are \<50%, with many patients unresponsive or inapt, necessitating b...
Detailed Description
In this study was assessed the associations among most frequently mutated genes and with clinicopathological features, as well as the prognostic significance of the presence of mutations in the top mu...
Eligibility Criteria
Inclusion
- Urothelial carcinoma located in bladder
- Patients treated with platinum regimens at the neoadjuvant . adjuvant setting
- Written informed consent for the use of biological material
Exclusion
- \-
Key Trial Info
Start Date :
May 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04872036
Start Date
May 1 2000
End Date
June 1 2017
Last Update
May 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.